The Food and Drug Administration (FDA) has granted fast approval to the drug ALC for treating people suffering from ALK-positive non-small-cell lung cancer (NSCLC) and experiencing resistance to crizotinib, or if their disease has progressed despite therapy with crizotinib [3]. Here, ALK is linked to non-small cell lung carcinoma.